Cancer Cell International (Apr 2022)

From inflammatory bowel disease to colorectal cancer: what’s the role of miRNAs?

  • Mostafa Vaghari-Tabari,
  • Niloufar Targhazeh,
  • Soheila Moein,
  • Durdi Qujeq,
  • Forough Alemi,
  • Maryam Majidina,
  • Simin Younesi,
  • Zatollah Asemi,
  • Bahman Yousefi

DOI
https://doi.org/10.1186/s12935-022-02557-3
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease with relapse and remission periods. Ulcerative colitis and Crohn’s disease are two major forms of the disease. IBD imposes a lot of sufferings on the patient and has many consequences; however, the most important is the increased risk of colorectal cancer, especially in patients with Ulcerative colitis. This risk is increased with increasing the duration of disease, thus preventing the progression of IBD to cancer is very important. Therefore, it is necessary to know the details of events contributed to the progression of IBD to cancer. In recent years, the importance of miRNAs as small molecules with 20–22 nucleotides has been recognized in pathophysiology of many diseases, in which IBD and colorectal cancer have not been excluded. As a result, the effectiveness of these small molecules as therapeutic target is hopefully confirmed. This paper has reviewed the related studies and findings about the role of miRNAs in the course of events that promote the progression of IBD to colorectal carcinoma, as well as a review about the effectiveness of some of these miRNAs as therapeutic targets.

Keywords